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Intrahepatic cholangiocarcinoma is a rare malignancy that originates from the epithelial cells of the intrahepatic bile ducts. 
Intrahepatic cholangiocarcinoma can metastasize in lymphatic chains, including the hepatoduodenal ligament, and it often 
invades adjacent organs or metastasizes to other visceral organs such as the lungs, bones, adrenal glands, and brain. However, 
distant skeletal muscle metastasis is very rare. Moreover, a metastatic skeletal muscle tumor rarely shows specific symptoms, 
making it difficult to identify in a routine examination. A 45-year-old man with a chief complaint of right upper quadrant abdominal 
pain was admitted to our hospital. Abdominal ultrasound and computed tomography with contrast enhancement showed a 
malignant mass in the right hepatic lobe, and 2-[
18F] fluoro-2-deoxy-D-glucose positron-emission tomography revealed distant 
skeletal muscle metastases in the thorax and buttock. The patient underwent an ultrasound-guided percutaneous needle biopsy 
for the metastatic low-echo masses in the skeletal muscle. (Korean J Hepatol 2010;16:325-328)
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INTRODUCTION
Cholangiocarcinomas arise from the epithelial cells of the bile 
ducts in the intrahepatic, perihilar, or distal (extrahepatic) biliary 
tree, and are exclusive of the gallbladder and ampulla of Vater. 
Common symptoms include pruritus, abdominal pain, weight 
loss, and fever. Intrahepatic cholangiocarcinomas originate 
peripherally within the intrahepatic ducts of the liver parenchyma, 
and form 5~10% of cholangiocarcinomas.
1,2 Imaging studies are 
essential for the diagnosis of cholangiocarcinoma. Transabdominal 
ultrasound, contrast-enhanced, triple phase, and helical computed 
tomography, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, and percutaneous 
transhepatic cholangiopancreatography have been used to 
diagnose cholangiocarcinoma. Tumor markers such as carbohydrate 
antigen (CA) 19-9 and carcinoembryonic antigen (CEA) can be 
useful in conjunction with biopsy or brushings to confirm the 
diagnosis. It is often difficult to make a definite diagnosis of 
cholangiocarcinoma preoperatively. Ultrasound or CT-guided 
percutaneous biopsy should be considered to confirm. 
18F-fluoro- 
2-dexoy-D-glucose positron emission tomography is also useful 
for detecting lymph node metastasis, distant metastasis, and a 
recurrence of intrahepatic cholangiocarcinoma.
3
A complete surgical resection is the only curative treatment 
for cholangiocarcinoma.
2 Patients who have unresectable disease 
may need palliative therapies, such as surgical or endoscopic 
biliary drainage, chemotherapy, radiation therapy, or stenting.
4 
Intrahepatic cholangiocarcinomas often invade adjacent organs 
or metastasize to other visceral organs. However, skeletal muscle 
metastasis from cholangiocarcinoma is very rare. This report 
describes a case of skeletal muscle metastasis from an intrahepatic 
cholangiocarcinoma as the first distant metastasis that was 
identified on 2-[
18F] fluoro-2-dexoy-D-glucose positron emission 
tomography (
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Figure 1. Abdominal computed tomography (CT) findings. An 
ill-defined low-density lesion with peripheral intrahepatic duct 
dilatation (A, C). Lymph node metastases were evident at the 
hepatoduodenal, aortocaval, and left para-aortic areas (B).
 
Figure 2. Positron-emission tomography-computed tomography (PET-CT) findings. Soft-tissue metastasis was present in the right thoracic
back (p-SUV=8.9) (A), and the left buttock (p-SUV=4.5) (B).
CASE REPORT
A 45-year-old man was admitted to Department of Gastro-
enterology because of abdominal pain. An ultrasound report 
from another hospital showed a mixed echoic mass in hepatic 
segments VII and VIII that measured about 4.3×3.0 cm in 
diameter. About 10 years ago, he had taken renal biopsy due to 
proteinuria, however, the biopsy findings revealed no specific 
disease. He denied tobacco and alcohol use.
On physical examination, the patient was not icteric, but had 
right upper quadrant abdominal tenderness. Laboratory findings 
taken on admission were as follows: Hb 12.2 g/dl, WBC 
5.8×10
3/µl, platelets 164×10
3/µl, urea nitrogen 34.0 mg/dl, 
creatinine 3.6 mg/dl, aspartate aminotransaminase 22 IU/l, 
alanine aminotransaminase 15 IU/l, total bilirubin 0.37 mg/dl, 
amylase 183 IU/l, lipase 140 IU/l, HBsAg negative, anti-HCV 
negative, rapid plasma reagin non-reactive, alpha-fetoprotein 1.7 
ng/mg, PIVKA II 23 mAU/ml, CA19-9 574.8 U/ml. A 24-hour 
urinary protein excretion was 1,498 mg/day.
A contrast-enhanced CT of the liver showed a low-density 
mass in hepatic segments VII and VIII and enhanced lymph 
nodes, including the hepatoduodenal ligament and aortocaval 
and left para-aortic region, as well as a small amount of ascites in 
the early arterial phase (Fig. 1). A peripherally enhanced, 
low-density mass was revealed in the delayed phase. Intrahepatic 
cholangiocarcinoma was diagnosed based on the CT findings. 
He underwent 
18F-FDG PET, which showed a malignant mass in 
the right hepatic lobe (p-SUV=11.2), a metastasis to the 
retroperitoneal and right common iliac lymphatic chain, and a 
distal paraesophageal area around the celiac axis. A paraspinal 
muscle metastasis in the right thoracic back (p-SUV=8.9) and 
left gluteus minimus muscle metastasis (p-SUV=4.5) were also 
revealed (Fig. 2).
An ultrasound-guided percutaneous needle biopsy of the low 
echoic mass was performed at the left buttock area near the left 
iliac crest (Fig. 3). The pathologic findings revealed an adeno-
carcinoma that was positive for cytokeratin 7 and 19 but negative 
for cytokeratin 20 and CEA (Fig. 4).
The abdominal CT, 
18F-FDG PET findings, and histopathologic 
features were compatible with intrahepatic cholangiocarcinoma 
with a distant skeletal muscle metastasis.
DISCUSSION
Biliary tract cancers are divided into cancers of the gall 
bladder, extrahepatic ducts, and the ampulla of Vater, and 
intrahepatic biliary tumors are classified as primary liver cancers.
1 
Intrahepatic cholangiocarcinoma is a malignant tumor arising 
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Figure 3. Ultrasonography image of the left buttock area. A 
low-echo mass lesion in a muscle layer was evident around the 
left iliac crest (0.5×1 cm
2). 
   
Figure. 4. Microscopic findings of a muscle biopsy. Neoplastic glandular infiltration was present in the skeletal muscle, suggesting 
metastatic adenocarcinoma (hematoxylin and eosin, ×200) (A). Neoplastic glands were positive in cytokeratin 7 immunostaining (×200)
(B), and negative in cytokeratin 20 staining (×200) (C).
from the epithelial cells of the intrahepatic bile ducts. Intrahepatic 
cholangiocarcinomas initially present as mass-forming lesions, 
and obstructive symptoms are rare.
4 Fever, night sweats, and 
weight loss may occur in addition to right upper quadrant 
abdominal pain.
4 Without clear reasons, the incidence of 
intrahepatic cholangiocarcinoma has been increasing over the 
past two decades in Europe, North America, Asia, Japan, and 
Australia.
5 Some of this may be attributable to new diagnostic 
methods identifying biliary malignancies that have previously 
not been diagnosed.
6
The major metastatic pattern for intrahepatic cholangiocar-
cinomas is early lymphatic spread. The hepatoduodenal ligament 
is the most common site for lymph node metastasis irrespective 
of tumor location. In the majority of cases, intrahepatic 
cholangiocarcinomas involve the lymph nodes of the hepato-
duodenal ligament or those along the common hepatic artery.
7,8 
Cholangiocarcinomas have often metastasized to distant organs, 
and 
18F-FDG PET is of value in discovering unsuspected distant 
metastases of cholangiocarcinoma.
3,9 Other investigators showed 
that nine distant metastatic lesions were detected by 
18F-FDG 
PET that were not detected using other imaging modalities.
10 
Because surgical resection is the only curative treatment of 
intrahepatic cholangiocarcinoma, accurate staging with 
18F-FDG 
PET is useful for appropriate management.
Although skeletal muscle accounts for approximately 50% of 
the total body mass and receives a large volume of blood, distant 
skeletal muscle metastasis is very rare.
11 The reason is not well 
elucidated. The effect of lactic acid on tumor cell production,
12 
the influence of variable and turbulent blood flow, β-adrenergic 
stimulation, tissue oxygen levels, and host immune response 
may provide protective mechanisms to skeletal muscle.
13 
Moreover, protease inhibitors in the muscle extracellular matrix 
may resist cancer cell invasion.
14 
Skeletal muscle metastasis is not generally explored until 
patients complain of symptoms such as localized pain or a 
palpable mass. Besides, intrahepatic cholangiocarcinomas are 
highly lethal, as most are locally advanced at presentation. This 
might be why distant skeletal muscle metastases from intrahepatic 
cholangiocarcinomas are rarely reported. 
In our case, asymptomatic skeletal muscle metastasis was 
diagnosed by 
18F-FDG PET during the initial examination in the 
patients with intrahepatic cholangiocarcinoma.
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